STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

Iowa Medicaid Drug Utilization Review (DUR) Commission

August 7, 2024

Location‡: Grimes State Office Building
Room B100
400 E 14th Street
Des Moines, IA 50319
No Virtual Option

Time: 9:30 a.m. – 1:30 p.m. CT

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the May 1, 2024 Meeting Minutes
    b) May 2024 DUR Recommendation Letter to DHHS
    c) Annual Chair and Vice Chair Elections
    d) Annual Conflict of Interest Disclosure
    e) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Iowa Total Care
    b) Wellpoint Iowa
    c) Molina Healthcare of Iowa
    d) Fee-for-Service
    e) Comparative Summary
5. Public Comment* (See attached Conflict of Interest Disclosure)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
    - Written – Must submit written comments and a completed conflict of interest disclosure.
    - **All submissions must be received no later than 4:30 p.m. CST July 31, 2024.**
    - Email to pba_iadur@optum.com
6. Retrospective DUR
    a) Data Presentation(s)
        i. Stimulant Medication Utilization without Supporting Diagnosis
        ii. Non-Selective Beta-Blockers in Asthma
    b) Proposal(s)
        i. Monitoring Prescribing of Antipsychotic Medications in Adults
        ii. Triple Therapy – Opioid, Benzodiazepine, and Muscle Relaxant
    c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Break (10 minutes)

8. Prior Authorization
    a) Biologicals for Inflammatory Bowel Disease – Initial Review
    b) Incretin Mimetics for Non-Diabetes Indications – Initial Review
    c) Janus Kinase Inhibitors – Initial Review
    d) Maralixibat (Livmarli) – Initial Review
    e) Omalizumab (Xolair) – Initial Review
    f) Oral Glucocorticoids for Duchenne Muscular Dystrophy – Initial Review
    g) Tralokinumab (Adbry) - Initial Review
    h) Zuranolone (Zurzuvae) – Initial Review
    i) Antidiabetic Non-Insulin Agents – Second review
    j) Biologicals for Axial Spondyloarthritis – Second Review
    k) Biologicals for Plaque Psoriasis – Second Review
9. Miscellaneous
    a) DUR Digest Vol. 36, No. 2 – Second Review
10. MedWatch

    FDA Approves New Treatment for Uncomplicated Urinary Tract Infections

    FDA alerts health care professionals of pregnancy problems associated with thiopurines
11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Speakers who fail to submit or turn in their conflict-of-interest disclosure form late will have their request to speak denied or will not have their comments shared.

‡ Always check the DUR website for updates regarding meeting location, as this can change after the initial posting of the agenda.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
November 6, 2024
Location: TBD